Campylobacter jejuni bacteremia and Guillain-Barré syndrome in a patient with GVHD after allogeneic BMT.
Guillain-Barré syndrome is a rare neurologic complication after allogeneic BMT. In the non-transplant setting, Guillain-Barré syndrome has typically been associated with antecedent acute infections and numerous reports have suggested an association between Campylobacter jejuni infection and the subsequent development of Guillain-Barré syndrome. Thus far, however, reports of C. jejuni-associated Guillain-Barré syndrome have been limited to gastrointestinal C. jejuni infections and none has been reported in BMT transplant patients. We report a case of C. jejuni bacteremia associated with Guillain-Barré syndrome that developed in a patient with chronic GVHD approximately 1 year after allogeneic BMT. The patient was treated with intravenous immunoglobulin and intravenous ciprofloxacin and had partial recovery. Our report illustrates that Guillain-Barré syndrome can occur in association with C. jejuni bacteremia and is a rare cause of polyneuropathy after BMT.
Hagensee
M E
ME
Department of Medicine, University of Washington, Seattle.
Benyunes
M
M
Miller
J A
JA
Spach
D H
DH
D016470:Bacteremia / Q000150:complications* / Q000188:drug therapy / Q000209:etiology*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002169:Campylobacter Infections / Q000150:complications* / Q000188:drug therapy / Q000209:etiology*; D016123:Campylobacter jejuni; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000150:complications* / Q000209:etiology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011129:Polyradiculoneuropathy / Q000188:drug therapy / Q000209:etiology*
D016756:Immunoglobulins, Intravenous; D002939:Ciprofloxacin